Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)

Decompensated Cirrhosis Clinical Trial

Official title:

A Phase 1 Dose Escalation Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Decompensated Cirrhosis (MSC-DLC-1)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05227846
• Other study ID #: MSC-DLC-1
• Status: Recruiting
• Phase: Phase 1
• Start date: March 22, 2022
• Est. completion date: March 1, 2025

Study information

• Verified date: April 2023
• Source: Beijing 302 Hospital
• Contact: Lei Shi, MD,PhD
• Phone: 86-10-66949623
• Email: shilei302[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open label, dose escalation clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis. The purpose of this study is to assess the safety of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.

Description:

The primary objective of this study is to assess the safety of intravenous infusion of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: March 1, 2025
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Willing to provide written informed consent;

2. Aged 18 to 75 years (including 18 and 75 years), male or female;

3. Patients diagnosed with decompensated liver cirrhosis based on clinical findings, laboratory tests, imaging findings and/or representative pathological findings (decompensated liver cirrhosis is defined as the occurrence of at least one serious complication, including esophageal and gastric varices bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis and other serious complications);

4. Child-Turcotte-Pugh (CTP) score 7 to 12 points.

Exclusion Criteria:

1. Appearance of active variceal bleeding, overt hepatic encephalopathy (HE), refractory ascites or hepatorenal syndrome within 1 month prior to screening visit.

2. Uncontrolled severe infection within 2 weeks of screening.

3. Hepatitis B virus (HBV) DNA = detection limit at the time of screening.

4. Patients with hepatitis B virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HBV for less than 12 months.

5. Patients with hepatitis C virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HCV for less than 12 months.

6. Patients under treatment with corticosteroids for autoimmune hepatitis for less than 6 months.

7. Trans-jugular intrahepatic portosystemic shunts (TIPS) insertion within 6 months prior to study inclusion.

8. Active drinkers with alcohol-related decompensated cirrhosis are unwilling to stop alcohol abuse after inclusion.

9. Severe jaundice (serum total bilirubin level = 170µmol/L); Significant renal insufficiency (serum creatinine = 1.2 times upper normal limit); Severe electrolyte abnormality (serum sodium level < 125 mmol/L); Severe leukopenia (white blood cell count < 1 × 10E9/L).

10. Patients with biliary obstruction, hepatic vein, portal vein, splenic vein thrombosis and portal vein spongiosis.

11. Patients with surgical history such as splenic cut-off flow and portal body shunt.

12. Patients with confirmed or suspected malignancies.

13. Patients with a prior history of major organ transplantation or complicated with significant disease of heart, lung, kidney, blood, endocrine and other systems.

14. Drug abuse, drug dependence and patients who receive methadone treatment or with psychosis.

15. HIV seropositivity.

16. Those who have received blood transfusion or other blood products within 1 month prior to screening visit.

17. Pregnancy, lactation or with recent fertility plan.

18. Highly allergic or have a history of severe allergies.

19. Participants in other clinical trials within the last 3 months.

20. Any other clinical condition which the investigator considers would make the patient unsuitable for the trial.

Related Conditions & MeSH terms

• Decompensated Cirrhosis
• Fibrosis
• Liver Cirrhosis

Intervention

Biological:
• Human Umbilical Cord-derived Mesenchymal Stem Cells
Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.

Locations

Country	Name	City	State
China	Beijing 302 Hospital	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Beijing 302 Hospital	VCANBIO Cell & Gene Engineering Corporation, Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events Incidence of Adverse Events		from baseline to 28th day
Primary	Change in Model for End-Stage Liver Disease (MELD) score from baseline to 28th day	The Model for End-stage Liver Disease (MELD) is a scoring system that evaluates the liver function reserve and prognosis of patients with chronic liver disease by creatinine, international normalized ratio (INR), and bilirubin-conjugated cirrhosis etiology.; The MELD score is calculated by the formula: R = 9.6 × ln (creatinine mg/dl) + 3.8 × ln (bilirubin mg/dl) + 11.2 × ln (INR) + 6.4 × etiology, and the results are taken as integers. ( 0 for cholestatic and alcoholic cirrhosis and 1 for other causes of cirrhosis such as viruses).	at 28th day
Secondary	Change in Model for End-Stage Liver Disease (MELD) score from baseline to 3 days, 7days, 14 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, and 24 months		3 days, 14 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, and 24 months
Secondary	Incidence of each complication associated with decompensated cirrhosis		up to 24 months
Secondary	liver transplant-free survival		up to 24 months
Secondary	Incidence of liver failure		up to 24 months
Secondary	plasma albumin (ALB)		up to 24 months
Secondary	plasma prealbumin (PALB)		up to 24 months
Secondary	total bilirubin (TBIL)		up to 24 months
Secondary	serum cholinesterase (CHE)		up to 24 months
Secondary	prothrombin time (PT)	Prothrombin time (PT) is a blood test that measures the time it takes for plasma to clot, to check for bleeding problems, or to check whether medicine to prevent blood clots is working.	up to 24 months
Secondary	Child-Turcotte-Pugh (CTP) score	Child-Turcotte-Pugh (CTP) score is a scoring system that evaluates the liver function.; Maximum is 15, minimum is 5. Higher scores mean a worse outcome.	up to 24 months
Secondary	EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)	Quality of life assessment. Maximum is 5, minimum is 1. Lower scores mean a better outcome.	up to 24 months
Secondary	Incidence of liver cancer		up to 24 months
Secondary	ChronicLiver Disease Questionnaire (CLDQ)	Quality of life assessment. The Chronic Liver Disease Questionnaire (CLDQ) was developed as an evaluative instrument to measure longitudinal change in health status within individuals with chronic liver disease. In addition to measuring both physical and mental health, the instrument was designed to be a disease-specific tool for assessing areas of function important to patients with chronic liver disease. Maximum is 7, minimum is 1. Higher scores mean a better outcome.	up to 24 months